The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Debiopharm Group
 
Employment - Debiopharm Group
Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
Cinta Hierro
No Relationships to Disclose
 
Rebecca Suk Heist
Honoraria - ARIAD; Boehringer Ingelheim
Research Funding - Abbvie; Celgene; Debiopharm Group; Millennium; Mirati Therapeutics; Novartis; Roche
 
James M. Cleary
Honoraria - Agios
Research Funding - Merck
Travel, Accommodations, Expenses - Roche
 
Funda Meric-Bernstam
Honoraria - Genentech; Roche
Consulting or Advisory Role - Celgene; Clearlight Diagnostics; Genentech; Inflection Biosciences; Novartis; Pieris Pharmaceuticals; Roche
Research Funding - Aileron Therapeutics; AstraZeneca; Bayer; Calithera Biosciences; Curis; CytomX Therapeutics; Debiopharm Group; Effective Pharmaceuticals; Genentech; Jounce Therapeutics; Novartis; PUMA Biotechnology; Taiho Pharmaceutical; Verastem; Zymeworks
 
Leena Gandhi
Honoraria - Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; Merck; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Nobuya Ishii
Employment - Chugai Pharma
 
Yulia Kirpicheva
No Relationships to Disclose
 
Valerie Nicolas-Metral
Employment - Debiopharm Group
 
Anna Pokorska-Bocci
Employment - Debiopharm Group
 
Daniela Purcea
No Relationships to Disclose
 
Anne Vaslin
Employment - Debiopharm Group
 
Corinne Moulon
Employment - Debiopharm Group
 
Claudio Zanna
Employment - Debiopharm Group
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Clovis Oncology; Genentech; Lilly; Loxo; Merck; miRNA Therapeutics; Novartis; Oncoceutics; Roche; Sanofi; Tioma Therapeutics
Research Funding - Novartis; Sanofi
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda
 
Jose Baselga
Leadership - Infinity Pharmaceuticals; Varian Medical Systems
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems
Consulting or Advisory Role - Eli Lilly, Novartis; GRAIL